Cogent Biosciences logo
Cogent Biosciences
COGT | NASDAQ
Chart Builder DCF Calculator
$27.44
-$1.12 (-3.92%)
At close: Nov 16, 2026, 4:00 PM ET
$27.73
+$0.29 (+1.06%)
After-hours: Nov 16, 2026, 7:50 PM ET

Cogent Biosciences Company Profile

Company profile explained

Company Profile

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Key Executives

Name Position
Andrew R. Robbins President, Chief Executive Officer & Director
Brad Barnett Chief Technology Officer
Erin Schellhammer Chief People Officer
Evan D. Kearns Chief Legal Officer & Corporate Secretary
John L. Green Chief Financial Officer & Principal Accounting Officer
Abb Hayden Senior Vice President of Sales
Christi Waarich Senior Director of Investor Relations
Cole Pinnow Chief Commercial Officer
Jessica Sachs Chief Medical Officer
John Edward Robinson Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 05, 2026 4 Filing
Sep 02, 2026 8-K Current Report
Aug 31, 2026 4 Filing
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 10, 2026 8-K Current Report
Aug 10, 2026 424B5 Filing
Aug 10, 2026 10-Q Quarterly Report
Aug 10, 2026 8-K Current Report
Jul 31, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Cogent Biosciences
Cogent Biosciences logo
Country United States
IPO Date Mar 29, 2018
Industry Biotechnology
Sector Healthcare
Employees 258
CEO Andrew R. Robbins

Contact Details

180 Third Avenue Waltham, Massachusetts 02451 United States

Stock Details

Ticker Symbol COGT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001622229
CUSIP Number 19240Q201
ISIN Number US19240Q2012
SIC Code 2834

Recent News

More News ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.